retatrutide triple agonist glp-1 gip glucagon phase 2 results Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Dual and Triple Gut Peptide

CVD: Cardiovascular Disease Although several in-line GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs have approved indications beyond T2D and overweight/ obesity, US Pharmacopeia Drug Classification (USP DC) 2025 limits classification to categories/classes according to their primary diagnosis (e.g., antidiabetic

Since 2025, the FDA has also flagged compounding facilities for safety reporting failures, such as concealing a patient's hospitalization for gastrointestinal issues after using compounded semaglutide

The gold standard

Medications get absorbed at different rates depending on the spot

Choose your injection site Three areas of the body work well for subcutaneous GLP-1 injections